Considerations for treatment duration in responders to immune checkpoint inhibitors
JournalJournal for ImmunoTherapy of Cancer
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractImmune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially paid to how much therapy would be needed for a durable response. As the early immunotherapy trials have matured past 10 years, a significant per cent of patients have demonstrated durable responses; it is now time to determine whether patients have been overtreated, and if durable remissions can still be achieved with less therapy, limiting the physical and financial toxicity associated with years of treatment. Well-designed trials are needed to identify optimal duration of therapy, and to define biomarkers to predict who would benefit from shorter courses of immunotherapy. Here, we outline key questions related to health, financial and societal toxicities of over treating with ICI and present four unique clinical trials aimed at exposing criteria for early cessation of ICI. Taken together, there is a serious liability to overtreating patients with ICI and future work is warranted to determine when it is safe to stop ICI. Copyright 2021 BMJ Publishing Group. All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15195
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
- Authors: Michielin O, Lalani AK, Robert C, Sharma P, Peters S
- Issue date: 2022 Jan
- Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
- Authors: Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, Ingle M, Brown A, Gujral D, Partridge S, Sarwar N, Gonzalez M, Bendle M, Lewanski C, Newsom-Davis T, Allara E, Bower M
- Issue date: 2019 Dec 1
- Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.
- Authors: Robert C, Marabelle A, Herrscher H, Caramella C, Rouby P, Fizazi K, Besse B
- Issue date: 2020 Nov
- Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis.
- Authors: Osipov A, Lim SJ, Popovic A, Azad NS, Laheru DA, Zheng L, Jaffee EM, Wang H, Yarchoan M
- Issue date: 2020 Sep 15
- Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
- Authors: Yao L, Jia G, Lu L, Bao Y, Ma W
- Issue date: 2020 Aug